Sanofi
-
Sanofi expands antibody partnership with Regeneron in US$8B deal to strengthen immunology pipeline
Sanofi will pay Regeneron US$1 billion upfront, with development, regulatory, and commercial milestones potentially adding another US$ 7 billion.
-
Cheplapharm expands in-house manufacturing capabilities in major Sanofi deal
The deal builds on a relationship between the companies that began in 2014, including previous transfers of mature medicines from Sanofi to Cheplapharm.
-
Sanofi halts Amlitelimab Atopic Dermatitis pipeline ahead of dupixent patent expiry
The latest decision marks another setback for amlitelimab, which Sanofi had previously positioned as a potential successor to Dupixent, its best-selling immunology asset.
-
UAE health authorities approve Sanofi’s Tzield for broader use in type 1 diabetes
The approval expands the use of the therapy to delay the onset of Stage 3 Type 1 diabetes in children as young as one year old.
-
DOH partners with Sanofi to establish vaccine innovation center within HELM cluster
The proposed centre will operate within Abu Dhabi’s Health, Endurance, Longevity, and Medicine (HELM) Cluster, a strategic life sciences platform that integrates research, healthcare delivery, investment, commercialization, and biomanufacturing.
-
Sanofi invests US$212M in Toronto’s AI hub to accelerate drug innovation
The project is backed by a conditional grant of up to C$5 million (US$3.6 million) from the Ontario government through the Invest Ontario Fund.
-
Sanofi’s Nuvaxovid exhibits 50% fewer severe side effects than Moderna’s mRNA booster
Less than 10% of participants in the Nuvaxovid group experienced severe side effects that interfered with daily activities compared with 20% in the mNexspike group.
-
German CDMO Adragos acquires major Sanofi sterile injectables plant near Paris
The Maisons-Alfort plant, which previously operated under Sanofi’s ownership, specializes in fill-finish manufacturing at commercial scale.
-
Sanofi disinvests Brazilian generics unit Medley to EMS in USD500M deal
Rather than consolidating operations through plant closures, EMS intends to retain Medley’s existing facilities and invest in future expansion.
-
Sanofi acquires global rights to Sino Biopharmaceutical’s Anxu in USD1.53B deal
The agreement includes a USD135 million upfront payment to Sino Biopharmaceutical for worldwide rights, with up to USD1.39 billion in potential milestone payments based on development, regulatory approvals, and sales.